PREDICTION OF PULMONARY FIBROSIS AND THE DEVELOPMENT OF CHRONIC PULMONARY INSUFFICIENCY IN PATIENTS WHO HAVE UNDERGONE COVID-19
Abstract
After recovering from COVID-19, many patients complain about their health. Transferring Covid-19 does not mean that you can now forget about hospitals. Most people just remember about them. Complications after the virus are no less dangerous than the disease itself. Therefore, patients who have undergone coronavirus undergo in-depth medical examination. While we are feverishly developing an effective treatment for the acute phase of the virus, we should not forget about the serious consequences of the COVID-19. To do this, we will consider and try to analyze the most dangerous complications after COVID-19.
Purpose. To describe the results of the COVID-19 pandemic for the recovered, with a focus on the great need to identify biomarkers that contribute to identifying patients who may develop fibrous interstitial pulmonary pathology (pulmonary fibrosis) at the initial stage of the disease.
When detecting COVID-19 manifestations and performing further treatment, it should be borne in mind that the infectious process after the virus is eliminated from the body in most cases does not stop and can turn into long-term lung damage, in particular, fibrous interstitial lung disease.
In the literary review, the analysis of modern Russian and foreign (exclusively in English) scientific works significant in relation to the topic of the review and presented in the databases eLibrary, PubMed, Scopus and in the scientific electronic library "Cyberleninka" (Cyberleninka) is carried out.
Downloads
References
Игнатова Г.Л., Антонов В.Н. Терапевтические возможности реабилитации пациентов, перенесших COVID-19, с остаточными изменениями легочной ткани // Consilium Medicum. 2022. Т. 24, № 3. С. 177-181 (Ignatova G.L., Antonov V.N. Therapeutic possibilities of rehabilitation of patients who have undergone COVID-19 with residual changes in the lungs: A review. Consilium Medicum, 2022, vol. 24(3), pp. 177-181). https://doi.org/10.26442/20751753.2022.3.201427
Aneta A., Gianfranco S., Antonio P.B., Alessandro P., Federico F., Milijana J., Giulia G. Biomarkers in the management of acute heart failure: state of the art and role in COVID-19 era. ESC Heart Failure, 2021, vol. 8(6), pp. 4465-4483. https://doi.org/10.1002/ehf2.13595
Awad M.R., El-Gamel A., Hasleton P., Turner D.M., Sinnot P.J., Hutchinson I.V. Genotypic variation in the transforming growth factor-β1 gene. Transplantation, 1998, vol. 66(8), pp. 1014-1020. https://doi.org/10.1097/00007890-199810270-00009
Awano N., Inomata M., Kuse N., et al. Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019. Respir Investig, 2020, vol. 58(6), pp. 440-447. https://doi.org/10.1016%2Fj.resinv.2020.07.004
Cui H., Xie N., Thannickal V.J., Liu G. The code of non-coding RNAs in lung fibrosis. Cell Mol Life Sci, 2015. vol. 72(18), pp. 3507-3519. https://doi.org/10.1007/s00018-015-1939-6
Du Bois R. M. The genetic predisposition to interstitial lung disease. Chest, 2002. vol. 121, pp. 14-20.
Fulmer J.D., Sposovska M.S., von Gal F.R., Crystal R.G., Mittal K.K. Distribution of HLA antigens in idiopathic pulmonary fibrosis. Am Rev Respir Dis, 1978. vol. 118(1), pp. 141-147. https://doi.org/10.1164/arrd.1978.118.1.141
Geddes D.M., Webley M., Brewerton D.A., Turton C.W., Turner-Warwick M., Murphy A.H., Ward A.M. α1-Antitrypsin phenotypes in fibrosing alveolitis and rheumatoid arthritis. Lancet, 1977, pp. 1049-1051. https://doi.org/10.1016/s0140-6736(77)91883-9
Gordon A.C., Mouncey P.R., Al-Beidh F., et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med., 2021, vol. 384(16), pp. 1491-1502. https://doi.org/10.1056/NEJMoa2100433
Grifoni E., Valoriani A., Cei F., et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect, 2020. no. 81(3), pp. 452-482. https://doi.org/10.1016/j.jinf.2020.06.008
Hamai K., Iwamoto H., Ishikawa N., et al. Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis Markers, 2016, pp. 47-59. https://doi.org/10.1155/2016/4759040
Huang L.S., Mathew B., Li H., Zhao Y., Ma S.F., Noth I., Reddy S.P., Harijith A., Usatyuk P.V., Berdyshev E.V., Kaminski N., Zhou T., Zhang W., Zhang Y., Rehman J., Kotha S.R., Gurney T.O., Parinandi N.L., Lussier Y.A., Garcia J.G., Natarajan V. The mitochondrial cardiolipin remodeling enzyme lysocardiolipin acyltransferase is a novel target in pulmonary fibrosis. Am J Respir Crit Care Med, 2014, vol. 189(11), pp. 1402-1415. https://doi.org/10.1164/rccm.201310-1917oc
Hutyrová B., Pantelidis P., Drábek J., Zurková M., Kolek V., Lenhart K., Welsh K., du Bois R. M., Petrek M. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2002, vol. 165(2), pp. 148-151. https://doi.org/10.1164/ajrccm.165.2.2106004
Ikeda K., Chiba H., Nishikiori H., et al. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respir Res, 2020, vol. 21 (1), 316. https://doi.org/10.1186/s12931-020-01582-y
Inoue Y., Kaner R. J., Guiot J., et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases wth a progressive phenotype. Chest, 2020, vol. 158(2), pp. 646-659. https://doi.org/10.1016/j.chest.2020.03.037
Kaufmann C.C., Ahmed A., Burger A.L., Muthspiel M., Jäger B., Wojta J., Huber K. Biomarkers Associated with Cardiovascular Disease in COVID-19. Cells, 2022 Mar 8, vol. 11(6), 922. https://doi.org/10.3390/cells11060922
Khalil N., O'Connor R.N., Unruh H.W., Warren P.W., Flanders K.C., Kemp A., Bereznay O.H., Greenberg A.H. Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 1991, vol. 5(2), pp. 155-162. https://doi.org/10.1165/ajrcmb/5.2.155
Ko U.W., Cho E.J., Oh H.B., Koo H.J., Do K.H., Song J.W. Serum Krebs von den Lungen-6 level predicts disease progression in interstitial lung disease. PLoS One, 2020, vol. 15(12). https://doi.org/10.1371/journal.pone.0244114
Kropski J.A., Blackwell T.S., Loyd J.E. The genetic basis of idiopathic pulmonary fibrosis. Eur Respir J, 2015, vol. 45(6), pp. 1717-1727. https://doi.org/10.1183/09031936.00163814
Li P., Li J., Chen T., Wang H., Chu H., Chang J., Zang W., Wang Y., Ma Y., Du Y., Zhao G., Zhang G. Expression analysis of serum microRNAs in idiopathic pulmonary fibrosis. Int J Mol Med, 2014, vol. 33(6), pp. 1554-1562. https://doi.org/10.3892/ijmm.2014.1712
Mori M., Kida H., Morishita H., Goya S., Matsuoka H., Arai T., Osaki T., Tachibana I., Yamamoto S., Sakatani M., et al. Microsatellite instability in transforming growth factor-β1 type II receptor gene in alveolar lining epithelial cells of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 2001, vol. 24(4), pp. 398-404. https://doi.org/10.1165/ajrcmb.24.4.4206
Nakao A., Fujii M., Matsumura R., Kumano K., Saito Y., Miyazono K., Iwamoto I. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest, 1999, vol. 104(1), pp. 5-11. https://doi.org/10.1172/jci6094
Noth I., Zhang Y., Ma S. F., Flores C., Barber M., Huang Y., Broderick S. M., Wade M. S., Hysi P., Scuirba J., Richards T. J., Juan-Guardela B. M., Vij R., Han M. K., Martinez F. J., Kossen K., Seiwert S. D., Christie J. D., Nicolae D., Kaminski N., Garcia J. G. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med, 2013, vol. 1(4), pp. 307-309. https://doi.org/10.1016/s2213-2600(13)70045-6
Pantelidis P., Fanning G. C., Wells A. U., Wellsh K. I., du Bois R. M. Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2001, vol. 163(6), pp. 1432-1436. https://doi.org/10.1164/ajrccm.163.6.2006064
Renzoni E., Lympany P., Sestini P., Pantelidis P., Wells A., Black C., Welsh K., Bunn C., Knight C., Foley P., et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum, 2000, vol. 43(7), pp. 1633-1640. https://doi.org/10.1002/1529-0131(200007)43:7%3C1633::aid-anr29%3E3.0.co;2-9
Riha R. L., Yang I. A., Rabnott G. C., Tunnicliffe A. M., Fong K. M., Zimmerman P. V. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J., 2004, vol. 34(3), pp. 126-129. https://doi.org/10.1111/j.1444-0903.2004.00503.x
Santana A., Saxena B., Noble N. A., Gold L. I., Marshall B.C. Increased expression of transforming growth factor β isoforms (β1, β2, β3) in bleomycin induced pulmonary fibrosis. Am J Respir Cell Mol Biol, 1995, vol. 13(1), pp. 34-44. https://doi.org/10.1165/ajrcmb.13.1.7541221
Selman M., King T. E., Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med, 2001, vol. 134(2), pp. 136-151. https://doi.org/10.7326/0003-4819-134-2-200101160-00015
Stock C.J., Soto H., Fonseca C., Banya W.A., Molyneaux P.L., Adam ali H., Russell A.M., Denton C.P., Abraham D.J., Hansel D.M., Nicholson A.G., Mahler T.M., Wells A.U., Lindahl G.E., Renzoni E.A. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax, 2013, vol. 68(5), pp. 436-441. https://doi.org/10.1136/thoraxjnl-2012-201786
Stuart B.D., Lee J.S., Kozlitina J., Noth I., Devine M.S., Glazer C.S., Torres F., Kaza V., Girod C.E., Jones K.D., Elicker B.M., Ma S.F., Vij R., Collard H.R., Wolters P.J., Garcin C.K. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med, 2014, vol. 2(7), pp. 557-565. https://doi.org/10.1016/s2213-2600(14)70124-9
Tzouvelekis A., Herazo-Maya J. D., Slade M., et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology, 2017, vol. 22(3), pp. 486-493. https://doi.org/10.1111%2Fresp.12920
Vázquez de Lara L., Becerril C., Montaño M., et al. Surfactant components modulate fibroblast apoptosis and type I collagen and collagenase-1 expression. Am J Physiol Lung Cell Mol Physiol, 2000, vol. 279(5). https://doi.org/10.1152/ajplung.2000.279.5.l950
Whyte M., Hubbard R., Meliconi R., Whidborne M., Eaton V., Bingle C., Timms J., Duff G., Facchini A., Pacilli A., et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphisms. Am J Respir Crit Care Med, 2000, vol. 162(2 Pt 1), pp. 755-758. https://doi.org/10.1164/ajrccm.162.2.9909053
Yang I.V., Schwartz D.A. Epigenetics of idiopathic pulmonary fibrosis. Transl Res, 2015, vol. 165(1), pp. 48-60. https://doi.org/10.1016/j.trsl.2014.03.011
Ziesche R., Hofbauer E., Witmann K., Petkov V., Block L. H. A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 1999, vol. 341(17), pp. 1264-1269. https://doi.org/10.1056/nejm199910213411703
Zou J. N., Sun L., Wang B. R., et al. The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest HRCT. PLoS One, 2021, vol. 16(3). https://doi.org/10.1371/journal.pone.0248957
Copyright (c) 2024 Diana B. Balinyan, Olga A. Efremova, Lyudmila A. Kamyshnikova, Vladislav A. Dubrova, Alexey Yu. Blagov
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
